cimetidine (tagamet) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cimetidine is a histamine H2-receptor antagonist. It reduces basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. It is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Cimetidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Cimetidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Cimetidine binds to an H2-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.1420 - $0.8237
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine | 2-cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine | acid-eze | acitak 200 | acitak 400 | acitak 800 | brumetadina | cimetag | cimetidin | cimetidina | cimetidine | cimétidine | cimetidine hcl | cimetidine hydrochloride | cimetidinum | dyspamet | galenamet | kentamet | n-cyano-n'-methyl-n''-(2-([(5-methyl-1h-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine | n''-cyano-n-methyl-n'-(2-{[(5-methyl-1h-imidazol-4-yl)methyl]thio}ethyl)guanidine | peptimax 200 | peptimax 400 | peptimax 800 | tagadine | tagamet | tagamet 100 | tagamet hb | tagamet hb 200 | tametin | ulcedin | ulcedine | ulcerex | ulcerfen | ultec | valmagen | zita

Organizations (62)

Research & Development (33)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (30)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (5)


 

Cystitis, Interstitial

Digestive System Diseases (approved 1995)

Duodenal Ulcer

Heartburn

Stomach Ulcer (approved 1995)

Experimental Indications - Clinical Trial Phases 1-4 (22)


 

Amyotrophic Lateral Sclerosis (Phase 1)

Anxiety Disorders (Phase 1)

Bacterial Infections (Phase 1)

Biomarkers (Early Phase 1)

Breast Neoplasms (Phase 2/Phase 3)

Dermatitis, Atopic (Phase 3)

Endometrial Neoplasms (Phase 2)

Healthy Volunteers (Phase 1)

Immunoglobulin E (Phase 3)

Intestinal Neoplasms (Phase 3)

Kidney Neoplasms (Phase 2)

Lactation (Phase 4)

Melanoma (Phase 2)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Peptic Ulcer (Phase 3)

Positron-Emission Tomography (Phase 1)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Protoporphyria, Erythropoietic (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Respiratory Aspiration (Phase 4)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial Organizations: 33

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue